Lv4
490 积分 2023-03-29 加入
Combinatorial strategies to target RAS-driven cancers
12天前
已完结
Targeting KRAS in cancer
12天前
已完结
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody
2个月前
已完结
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
4个月前
已完结
Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
5个月前
已完结
T-DXd effective in HER2-mutant NSCLC
6个月前
已完结
Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer
7个月前
已完结
Abstract LB324: BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models
7个月前
已关闭
Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy
9个月前
已完结
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy
10个月前
已完结
皖公网安备34019202002308
